Multimodality imaging of endocrine immune related adverse events: a primer for radiologists
- 9 January 2018
- journal article
- research article
- Published by Elsevier BV in Clinical Imaging
- Vol. 50, 96-103
- https://doi.org/10.1016/j.clinimag.2017.12.014
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapyActa Endocrinologica, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Hashimoto Thyroiditis: Part 1, Sonographic Analysis of the Nodular Form of Hashimoto ThyroiditisAmerican Journal of Roentgenology, 2010
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesPituitary, 2009
- Ipilimumab-Induced Hypophysitis: MR Imaging FindingsAmerican Journal of Neuroradiology, 2009
- Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic MelanomaJournal of Immunotherapy, 2006
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005